比那甫西颗粒治疗传统维吾尔医学热性感冒:多中心随机对照试验研究方案
本研究为多中心、随机、双盲、安慰剂对照的II期临床试验,计划纳入240例热性感冒患者,随机分为高剂量组、低剂量组和安慰剂组(1:1:1),每日服药两次、连续3天,主要结局为退热时间,旨在探索比那甫西颗粒的疗效、安全性和最佳治疗剂量。
要点
- 比那甫西颗粒治疗热性感冒的疗效、安全性和最佳剂量尚待验证。
- 试验采用多中心、随机、双盲、安慰剂对照设计,计划纳入240例。
- 主要结局为退热时间,次要结局包括退热清除时间、症状持续时间和维医症状评分变化。
核心结论
- 本研究旨在探索比那甫西颗粒治疗热性感冒的疗效、安全性和最佳治疗剂量。
- 这是首个针对维吾尔医药治疗普通感冒的安慰剂对照随机临床试验。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的II期临床试验,计划从中国五个中心纳入240例参与者。
- 参与者按1:1:1比例随机分配至高剂量组、低剂量组或安慰剂对照组。
- 所有合格患者每日服药两次,连续3天。
关键数值与推荐
- 主要结局为退热时间。
- 次要结局包括退热清除时间、主要症状及每一症状的持续时间、维医症状评分变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The common cold is a highly prevalent illness with significant impact on society and health care. Common cold with heat syndrome (CCHS) is one of the most common types based on syndrome differentiation by traditional Uighur medicine (TUM), which is widely used in Central Asia. The study is designed to explore the efficacy, safety and optimal therapeutic dosage of Binafuxi granules in treating CCHS. METHODS: This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Participants (n = 240) will be enrolled from five centers across China and randomly assigned to the high-dose group, low-dose group or placebo control group in a 1:1:1 ratio. All eligible patients will receive test drugs twice daily for 3 days. The primary outcome is the time to fever relief. Secondary outcomes include the time to fever clearance, duration of primary symptoms and each symptom and change in TUM symptom score. DISCUSSION: This is the first placebo-controlled randomized clinical trial of a Uighur medicine in treating common cold. It will provide robust evidence on the efficacy and safety of Binafuxi granules in the treatment of CCHS. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IIR-17013379 . Registered on 14 November 2017.
引用
- Min J, She B, Zhang X, et al. Binafuxi granules in the treatment of common cold with heat syndrome based on traditional Uighur medicine: study protocol for a multicenter randomized controlled trial. Trials. 2019. PMID: 30922355. doi:10.1186/s13063-019-3290-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。